Scholarlink

Background <p>The molecular mechanisms linking bile acid signaling to biliary fibrosis in hepatolithiasis are unclear. We investigated the role of the bile acid receptor TGR5 in driving fibrotic progression.</p> Methods <p>We employed an integrated strategy. TGR5 expression was assessed in human hepatolithiasis tissues and bioinformatics databases. A hepatolithiasis mouse model was compared with TGR5-knockout (TGR5-/-) mice, analyzing lipid metabolism, cholesterol transport, and fibrosis markers via ELISA, qPCR, and immunohistochemistry. In vitro, human intrahepatic biliary epithelial cells (HIBECs) were treated with bile acids, TGR5 agonists/inhibitors, and cAMP modulators. We assessed the cAMP/PKA/CREB pathway, epithelial-mesenchymal transition (EMT), and fibrosis.</p> Results <p>TGR5 was significantly overexpressed in hepatolithiasis tissues. Genetic deletion of TGR5 in mice alleviated metabolic disturbances and markedly reduced fibrosis markers (TGF-β1, α-SMA, Collagen I). In cholangiocytes, TGR5 activation stimulated the cAMP/PKA/CREB signaling cascade, promoting EMT and fibrosis. These pro-fibrotic effects were reversed by inhibiting TGR5 or cAMP. Mechanistically, TGR5-driven cAMP signaling induced CREB phosphorylation, leading to upregulated TGF-β1 expression, which sustains the fibrotic phenotype.</p> Conclusion <p>This study defines a critical pathogenic axis in hepatolithiasis, whereby TGR5 activation in cholangiocytes triggers cAMP/PKA/CREB signaling to promote EMT and biliary fibrosis via TGF-β1. Our findings directly implicate TGR5 as a central therapeutic target for mitigating fibrosis in this disease.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Activation of the TGR5/cAMP/PKA/CREB axis in cholangiocytes mediates epithelial-mesenchymal transition and fibrosis in hepatolithiasis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月20日

查看全文
  • Dan Tang,
  • Jiali Yang,
  • Xinhao Shi,
  • Xuanyu Gu,
  • Lijin Zhao

摘要

Background

The molecular mechanisms linking bile acid signaling to biliary fibrosis in hepatolithiasis are unclear. We investigated the role of the bile acid receptor TGR5 in driving fibrotic progression.

Methods

We employed an integrated strategy. TGR5 expression was assessed in human hepatolithiasis tissues and bioinformatics databases. A hepatolithiasis mouse model was compared with TGR5-knockout (TGR5-/-) mice, analyzing lipid metabolism, cholesterol transport, and fibrosis markers via ELISA, qPCR, and immunohistochemistry. In vitro, human intrahepatic biliary epithelial cells (HIBECs) were treated with bile acids, TGR5 agonists/inhibitors, and cAMP modulators. We assessed the cAMP/PKA/CREB pathway, epithelial-mesenchymal transition (EMT), and fibrosis.

Results

TGR5 was significantly overexpressed in hepatolithiasis tissues. Genetic deletion of TGR5 in mice alleviated metabolic disturbances and markedly reduced fibrosis markers (TGF-β1, α-SMA, Collagen I). In cholangiocytes, TGR5 activation stimulated the cAMP/PKA/CREB signaling cascade, promoting EMT and fibrosis. These pro-fibrotic effects were reversed by inhibiting TGR5 or cAMP. Mechanistically, TGR5-driven cAMP signaling induced CREB phosphorylation, leading to upregulated TGF-β1 expression, which sustains the fibrotic phenotype.

Conclusion

This study defines a critical pathogenic axis in hepatolithiasis, whereby TGR5 activation in cholangiocytes triggers cAMP/PKA/CREB signaling to promote EMT and biliary fibrosis via TGF-β1. Our findings directly implicate TGR5 as a central therapeutic target for mitigating fibrosis in this disease.

Graphical Abstract